{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:23:40Z","timestamp":1793064220527,"version":"4.5.0"},"reference-count":31,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,18]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The CASSIOPEIA trial demonstrated superior progression-free survival (PFS) with the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction\/consolidation, and with daratumumab maintenance vs observation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The companion study, CASSIOPET, assessed the prognostic value of premaintenance (PM) positron emission tomography (PET)\/computed tomography (CT) response, based on the standardized Deauville score on PFS and overall survival (OS), in addition to bone marrow (BM) minimal residual disease (MRD) detection by multiparameter flow cytometry (MFC) at 10\u20135 level. PM PET\/CT was available for 225 patients: 112 patients treated with daratumumab after D-VTd (59) or bortezomib, thalidomide, and dexamethasone (VTd; 53), and 113 patients followed by observation after D-VTd (56) or VTd (57). At PM, 92% of the 175 baseline PET-positive patients achieved PET negativity, with a longer PFS in univariate analysis (P = .019) and a major trend of prolonged OS (P = .056). In univariate analysis, patients who achieved both PET and MFC negativity were found to have a better PFS (P &amp;lt; .0001) than those who had at least 1 positive result. In daratumumab-treated patients, PM PET negativity was associated with prolonged PFS and OS in univariate analysis (P = .0023 and P = .033, respectively), and double MFC and PET negativity was independently associated with PFS by multivariate analysis (P = .0006). This study confirms the prognostic relevance of a PM PET response in patients with NDMM treated with daratumumab in addition to MRD detection by MFC at the BM level. This trial was registered at ww.clinicaltrials.gov as #NCT02541383.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030084","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:56:12Z","timestamp":1758740172000},"page":"3050-3058","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic value of premaintenance FDG PET\/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3417-0759","authenticated-orcid":false,"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"first","affiliation":[{"name":"1Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"},{"name":"2Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, Centre Hospitalier Universitaire Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Jamet","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0131-8689","authenticated-orcid":false,"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Toulouse, Universit\u00e9 de Toulouse, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[{"name":"5Department of Hematology, H\u00f4pital Haut L\u00e9v\u00eaque, University Hospital Bordeaux, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Caillot","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Centre Hospitalier Universitaire Dijon, H\u00f4pital Du Bocage, Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Centre Hospitalier Universitaire Lille, University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9822-4170","authenticated-orcid":false,"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Centre Hospitalier Universitaire Poitiers, H\u00f4pital la Mil\u00e9trie, Poitiers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Lymphoid Malignancies Unit, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-4058","authenticated-orcid":false,"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[{"name":"10Department of Nuclear Medicine, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[{"name":"11Department of Hematology, Centre Hospitalier Lyon-Sud H\u00e9matologie, Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Bailly","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"},{"name":"2Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, Centre Hospitalier Universitaire Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"12Department of Hematology, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"13Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8219-3592","authenticated-orcid":false,"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"},{"name":"2Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, Centre Hospitalier Universitaire Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-9483","authenticated-orcid":false,"given":"Bart","family":"de Keizer","sequence":"additional","affiliation":[{"name":"14Department of Nuclear Medicine and Radiology, University Medical Center Utrecht, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1580-6106","authenticated-orcid":false,"given":"Jill","family":"Corre","sequence":"additional","affiliation":[{"name":"15Hematology Laboratory, Unite de Genomique du Myelome, Institut Universitaire du Cancer Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0808-2237","authenticated-orcid":false,"given":"Pieter","family":"Sonneveld","sequence":"additional","affiliation":[{"name":"16Department of Hematology, Erasmus Medical Center Cancer Institute, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"2Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, Centre Hospitalier Universitaire Nantes, Nantes, France"},{"name":"17Department of Hematology, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6932-7322","authenticated-orcid":false,"given":"Thomas","family":"Carlier","sequence":"additional","affiliation":[{"name":"1Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"},{"name":"2Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, Centre Hospitalier Universitaire Nantes, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[{"name":"2Department of Nuclear Oncology, ICAGEN, reMoVE-B, INSERM, National Centre for Scientific Research, Centre de Recherche en Canc\u00e9rologie et Immunologie Int\u00e9gr\u00e9e Nantes Angers, Centre Hospitalier Universitaire Nantes, Nantes, France"},{"name":"17Department of Hematology, Centre Hospitalier Universitaire Nantes, Nantes Universit\u00e9, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9","key":"2025121811213276500_bib1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2967\/jnumed.122.264972","article-title":"New developments in myeloma treatment and response assessment","volume":"64","author":"Kraeber-Bod\u00e9r\u00e9","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"2025121811213276500_bib2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00259-024-06858-9","article-title":"EANM guidelines on the use of [18F]FDG PET\/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders","volume":"52","author":"Nanni","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"2025121811213276500_bib3","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2025121811213276500_bib4","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2009-03-213280","article-title":"F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma","volume":"114","author":"Bartel","year":"2009","journal-title":"Blood"},{"issue":"25","key":"2025121811213276500_bib5","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM\/DFCI 2009 trial: results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121811213276500_bib6","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.eclinm.2023.102017","article-title":"Impact of minimal residual disease standardised assessment by FDG-PET\/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial","volume":"60","author":"Zamagni","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025121811213276500_bib7","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025121811213276500_bib8","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S2352-3026(23)00030-3","article-title":"European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours","volume":"10","author":"Nanni","year":"2023","journal-title":"Lancet Haematol"},{"issue":"2","key":"2025121811213276500_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.20.00386","article-title":"Standardization of 18F-FDG\u2013PET\/CT according to Deauville criteria for metabolic complete response definition in newly diagnosed multiple myeloma","volume":"39","author":"Zamagni","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025121811213276500_bib10","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1148\/radiol.2019181949","article-title":"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)","volume":"291","author":"Messiou","year":"2019","journal-title":"Radiology"},{"issue":"23","key":"2025121811213276500_bib11","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025121811213276500_bib12","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Minimal residual disease predicts superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"12","key":"2025121811213276500_bib13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transpl"},{"issue":"25","key":"2025121811213276500_bib14","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025121811213276500_bib15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal residual disease assessment within the bone marrow of multiple myeloma: a review of caveats, clinical significance and future perspectives","volume":"9","author":"Romano","year":"2019","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2025121811213276500_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood.V130.Suppl_1.905.905","article-title":"Impact of next-generation flow (NGF) minimal residual disease (MRD) monitoring in multiple myeloma (MM): results from the Pethema\/GEM2012 trial [abstract]","volume":"130","author":"Paiva","year":"2017","journal-title":"Blood"},{"issue":"10192","key":"2025121811213276500_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2025121811213276500_bib18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"2025121811213276500_bib19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood.2024027620","article-title":"Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results","volume":"146","author":"Corre","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2025121811213276500_bib20","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3324\/haematol.2021.280051","article-title":"Prognostic value of positron emission tomography\/computed tomography in transplant eligible newly diagnosed multiple myeloma patients from CASSIOPEIA: the CASSIOPET study","volume":"108","author":"Kraeber-Bod\u00e9r\u00e9","year":"2023","journal-title":"Haematologica"},{"issue":"3","key":"2025121811213276500_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s00259-015-3200-9","article-title":"Image interpretation criteria for FDG PET\/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)","volume":"43","author":"Nanni","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025121811213276500_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017;16","journal-title":"Nat Commun"},{"issue":"7","key":"2025121811213276500_bib23","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"7","key":"2025121811213276500_bib24","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2967\/jnumed.121.262884","article-title":"Molecular signature of 18F-FDG PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study","volume":"63","author":"Alberge","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"2025121811213276500_bib25","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2025121811213276500_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2025121811213276500_bib27","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","article-title":"Low hexokinase-2 expression-associated false-negative 18F-FDG PET\/CT as a potential prognostic predictor in patients with multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2025121811213276500_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2025121811213276500_bib29","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International Myeloma Working Group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15","key":"2025121811213276500_bib30","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.3390\/ijms21155406","article-title":"Functional imaging for therapeutic assessment and minimal residual disease detection in multiple myeloma","volume":"21","author":"Jamet","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2025121811213276500_bib31","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s00259-024-06621-0","article-title":"[68Ga]Pentixafor PET\/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET\/CT","volume":"51","author":"Chen","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/25\/3050\/2476615\/blood_bld-2025-030084-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/25\/3050\/2476615\/blood_bld-2025-030084-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T16:21:44Z","timestamp":1766074904000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/25\/3050\/547450\/Prognostic-value-of-premaintenance-FDG-PET-CT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":31,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2025,12,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030084","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12,18]]},"published":{"date-parts":[[2025,12,18]]}}}